These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15207762)

  • 41. Is APD a promising drug in the treatment of severe osteogenesis imperfecta?
    Huaux JP; Lokietek W
    J Pediatr Orthop; 1988; 8(1):71-2. PubMed ID: 3335625
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Treatment of osteogenesis imperfecta with bisphosphonates].
    Tau C
    Medicina (B Aires); 2007; 67(4):389-95. PubMed ID: 17891938
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High levels of serum prostaglandin E2 in children with osteogenesis imperfecta are reduced by neridronate treatment.
    D'Eufemia P; Finocchiaro R; Celli M; Zambrano A; Tetti M; Villani C; Persiani P; Mari E; Zicari A
    Pediatr Res; 2008 Feb; 63(2):203-6. PubMed ID: 18091347
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of intrapulmonary percussive ventilation (IPV) in the management of pulmonary complications of an infant with osteogenesis imperfecta.
    Nino G; McNally P; Miske LJ; Hickey E; Panitch HB
    Pediatr Pulmonol; 2009 Nov; 44(11):1151-4. PubMed ID: 19824049
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alendronate treatment in osteogenesis imperfecta.
    Madenci E; Yilmaz K; Yilmaz M; Coskun Y
    J Clin Rheumatol; 2006 Apr; 12(2):53-6. PubMed ID: 16601536
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhaled nitric oxide in the management of preterm infants with severe respiratory failure.
    Su PH; Chen JY
    J Perinatol; 2008 Feb; 28(2):112-6. PubMed ID: 17989696
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reduction of plasma taurine level in children affected by osteogenesis imperfecta during bisphosphonate therapy.
    D'Eufemia P; Finocchiaro R; Zambrano A; Tetti M; Ferrucci V; Celli M
    Biomed Pharmacother; 2007 May; 61(4):235-40. PubMed ID: 17275249
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation and comparison of safety, convenience and cost of administering intravenous pamidronate infusions to children in the home and ambulatory care settings.
    Rush ET; DeHaai K; Kreikemeier RM; Lutz RE
    J Pediatr Endocrinol Metab; 2012; 25(5-6):493-7. PubMed ID: 22876544
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cyclic pamidronate treatment in Bruck syndrome: proposal of a new modality of treatment.
    Andiran N; Alikasifoglu A; Alanay Y; Yordam N
    Pediatr Int; 2008 Dec; 50(6):836-8. PubMed ID: 19067906
    [No Abstract]   [Full Text] [Related]  

  • 50. Osteogenesis imperfecta: rehabilitation approach with infants and young children.
    Binder H; Hawks L; Graybill G; Gerber NL; Weintrob JC
    Arch Phys Med Rehabil; 1984 Sep; 65(9):537-41. PubMed ID: 6477088
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Severe respiratory distress due to ileal duplication cyst in the newborn].
    Vuković J; Sovagović RG; Filipović-Grcić B; Hlupić L; Jelasić D
    Acta Med Croatica; 2006; 60(1):59-61. PubMed ID: 16802574
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents.
    Robinson RE; Nahata MC; Hayes JR; Batisky DL; Bates CM; Mahan JD
    Pharmacotherapy; 2004 Feb; 24(2):195-7. PubMed ID: 14998220
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synchronized ventilation of very-low-birth-weight infants; report of 6 years' experience.
    OZkan H; Duman N; Kumral A; Gülcan H
    J Matern Fetal Neonatal Med; 2004 Apr; 15(4):261-5. PubMed ID: 15280135
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pamidronate lines.
    Srinivasan R
    Indian Pediatr; 2005 Sep; 42(9):959-60. PubMed ID: 16208065
    [No Abstract]   [Full Text] [Related]  

  • 55. [Early use of BiPAP in the management of respiratory failure in an infant with osteogenesis imperfecta: case report].
    Vega-Briceño L; Contreras I; Sánchez I; Bertrand P
    Rev Med Chil; 2004 Jul; 132(7):861-4. PubMed ID: 15379335
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acute pseudogout after pamidronate infusion.
    Wendling D; Tisserand G; Griffond V; Saccomani C; Toussirot E
    Clin Rheumatol; 2008 Sep; 27(9):1205-6. PubMed ID: 18500436
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Frequency of respiratory deterioration after immunisation in preterm infants.
    Hacking DF; Davis PG; Wong E; Wheeler K; McVernon J
    J Paediatr Child Health; 2010 Dec; 46(12):742-8. PubMed ID: 20825611
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Electrocardiographic Q-Tc prolongation associated with infusion of intravenous pamidronate disodium.
    Varma N; Kerrigan GN
    Postgrad Med J; 1993 Jun; 69(812):497-8. PubMed ID: 8208655
    [No Abstract]   [Full Text] [Related]  

  • 59. [Treatment of osteogenesis imperfecta with calcitonin].
    Socha J; Brzozowska-Wolnik D; Ignyś I; Stańska M
    Pediatr Pol; 1982; 57(9):735-7. PubMed ID: 6763191
    [No Abstract]   [Full Text] [Related]  

  • 60. Osteogenesis imperfecta. Therapeutic challenge.
    Pierog SH; Fontana VJ; Ferrara A
    N Y State J Med; 1969 Jan; 69(2):310-3. PubMed ID: 5251302
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.